Saturday 17 October 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
7.08
0.52
−6.84%
Follow TKNO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 4 | 1 | 2 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 64.73 | 64.73 | — |
Altman Z-Score |
1.83 | 4.95 | 0.56 | 0.90 | 9.08 | — | — | — |
P/S ratio |
5.02 | 10.34 | 3.30 | 3.81 | 8.93 | 2.63 | 2.63 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(1.59) | (0.61) | 0.14 | 0.80 | 9.50 | 2.30 | 5.09 | — |
Beneish M-Score |
(3.04) | (2.70) | (2.93) | (3.43) | (3.01) | (1.64) | — | — |
P/Operating CF |
(439.90) | (417.02) | (41.81) | (19.66) | (106.90) | 37.48 | 37.48 | — |
P/B ratio |
2.96 | 4.74 | 1.34 | 1.58 | 2.30 | 5.53 | 5.53 | — |
Price to Tangible BV |
3.58 | 5.63 | 1.60 | 1.92 | 3.05 | 5.53 | 5.53 | — |
EV/Sales |
4.91 | 9.89 | 2.93 | 3.38 | 6.88 | 2.55 | 2.55 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.06 | 19.06 | — |
EV/Operating CF |
(23.02) | (30.14) | (5.71) | (5.10) | (27.99) | 17.78 | 17.78 | — |
EV/FCF |
(20.33) | (27.89) | (4.05) | (2.52) | (8.77) | (19.63) | (19.63) | — |
Quick Ratio |
3.44 | 3.10 | 3.65 | 4.28 | 12.06 | 2.82 | 2.27 | — |
Current Ratio |
4.58 | 3.82 | 5.14 | 5.62 | 13.07 | 4.14 | 2.76 | — |
Net Debt/EBITDA |
0.75 | 0.86 | 0.52 | 0.39 | 8.41 | (0.76) | 3.22 | — |
Debt/Assets |
12.67% | 11.36% | 10.31% | 15.89% | 7.13% | 0.00% | 0.08% | 0.00% |
Debt/Equity |
0.19 | 0.16 | 0.15 | 0.24 | 0.08 | 0.00 | 0.00 | — |
Asset Turnover |
0.36 | 0.31 | 0.26 | 0.26 | 0.32 | 0.52 | 0.71 | — |
Operating CF/Net income |
0.50 | 0.46 | 0.51 | 0.58 | 0.93 | 4.12 | (1.67) | — |
Capex/Depreciation |
(0.19) | (0.15) | (1.26) | (8.18) | (6.59) | (2.67) | 0.00 | — |
Interest Coverage |
(23.91) | (38.06) | (42.69) | (233.14) | — | 53.60 | (139.15) | — |
| (22.83%) | (31.02%) | (38.73%) | (39.05%) | (12.26%) | 4.10% | (9.70%) | — | |
| (15.52%) | (21.62%) | (26.19%) | (29.78%) | (8.55%) | 1.00% | (4.92%) | — | |
ROIC |
(17.52%) | (24.95%) | (29.71%) | (37.92%) | (11.11%) | 25.04% | 0.00% | — |
Return on Tangible Assets |
(25.12%) | (34.59%) | (42.20%) | (46.61%) | (7.95%) | 2.71% | (9.42%) | — |
Average Days of Receivables |
41.60 | 41.70 | 39.28 | 37.74 | 57.92 | 70.44 | 52.45 | — |
Research and Development Expense of Revenue |
5.42% | 7.31% | 15.18% | 18.68% | 11.69% | 4.82% | 3.80% | — |
Selling, General and Administrative Expense of Revenue |
66.81% | 78.08% | 94.81% | 90.41% | 65.51% | 33.35% | 55.35% | — |
Intangible Assets out of Total Assets |
0.12 | 0.11 | 0.11 | 0.12 | 0.21 | 0.58 | 0.64 | 0.00 |
Share Based Compensation of Revenue |
8.46% | 9.71% | 11.28% | 8.96% | 4.20% | 0.96% | 0.00% | — |
Graham Net Nets |
0.00 | 0.02 | 0.06 | 0.06 | 0.24 | 0.29 | 0.29 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.89 | 0.00 | — |
Earnings Yield |
(8.68%) | (7.07%) | (30.53%) | (30.07%) | (4.65%) | 1.54% | 1.54% | — |
Free Cash Flow Yield |
(4.82%) | (3.43%) | (21.96%) | (35.20%) | (8.79%) | (4.94%) | (4.94%) | — |
Revenue per Share |
0.76 | 0.81 | 1.15 | 1.47 | 2.29 | 8.70 | 0.80 | — |
Operating CF per Share |
(0.16) | (0.27) | (0.59) | (0.98) | (0.56) | 0.70 | 0.09 | — |
Capex per Share |
(0.02) | (0.02) | (0.24) | (1.00) | (1.24) | (1.52) | 0.00 | — |
Free Cash Flow per Share |
(0.18) | (0.29) | (0.83) | (1.98) | (1.80) | (0.82) | 0.09 | — |
Cash per Share |
0.40 | 0.65 | 0.90 | 1.50 | 5.44 | 1.42 | 0.37 | — |
Shareholders Equity per Share |
1.29 | 1.76 | 2.83 | 3.56 | 8.90 | 4.66 | 1.86 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.29 | 1.76 | 2.83 | 3.56 | 8.90 | 4.66 | 1.86 | — |
Free Cash Flow |
(9.79) | (13.39) | (26.55) | (55.55) | (28.95) | (2.96) | 2.41 | — |
Working Capital |
26.97 | 31.57 | 36.79 | 50.27 | 93.46 | 12.45 | 9.84 | — |
Capital Expenditures |
(1.15) | (1.00) | (7.74) | (28.15) | (19.88) | (5.47) | (2.85) | — |
Net Current Asset Value |
(0.30) | 6.40 | 7.11 | 8.76 | 77.90 | (29.73) | 5.45 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.03 | 0.03 | 0.21 | 0.68 | 0.54 | 0.17 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.14 | 0.14 | 0.12 | 0.07 | 0.10 | 0.20 | 0.30 | — |
Cash ROIC |
(9.49%) | (10.60%) | (20.15%) | (33.40%) | (11.93%) | (13.52%) | 4.14% | — |
Accounts Receivable Turnover |
9.08 | 9.14 | 8.91 | 8.17 | 6.20 | 6.93 | 4.35 | — |
Accounts Payable Turnover |
24.58 | 26.33 | 13.39 | 10.20 | 9.93 | 11.27 | 10.89 | — |
Inventory Turnover |
3.91 | 3.32 | 2.21 | 2.71 | 4.29 | 4.41 | 4.26 | — |
Average Days of Payables |
18.57 | 9.87 | 20.65 | 37.33 | 42.58 | 44.07 | 21.43 | — |
Days of Inventory on Hand |
95.08 | 81.35 | 160.37 | 186.69 | 102.16 | 96.55 | 71.60 | — |
Average Receivables |
4.47 | 4.13 | 4.12 | 5.07 | 5.95 | 4.51 | 4.78 | — |
Average Payables |
1.10 | 1.16 | 1.97 | 2.35 | 1.94 | 1.20 | 1.20 | — |
Average Inventory |
6.93 | 9.20 | 11.92 | 8.82 | 4.49 | 3.07 | 3.07 | — |
Average Assets |
111.18 | 123.68 | 140.42 | 159.39 | 114.71 | 60.71 | 29.26 | — |
Average Common Equity |
75.58 | 86.22 | 94.96 | 121.54 | 79.99 | 14.84 | 14.84 | — |
Columns are period end dates